Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development

David Franco, Wenjing Li, Fang Qing, Cristina T. Stoyanov, Thomas Moran, Charles M. Rice, David D. Ho

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The failure to develop an effective vaccine against HIV-1 infection has led the research community to seek new ways of raising qualitatively different antibody and cellular immune responses. Towards this goal, we investigated the yellow fever 17D vaccine strain (YF17D), one of the most effective vaccines ever made, as a platform for HIV-1 vaccine development. A test antigen, HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24), or between the envelope and the first non-structural protein (YF-E/p24/NS1). In vitro characterization of these recombinants indicated that the gene insert was more stable in the context of YF-E/p24/NS1. This was confirmed in immunogenicity studies in mice. CD8+ IFN-γ T-cell responses against p24 were elicited by the YF17D recombinants, as were specific CD4+ T cells expressing IFN-γ and IL-2. A balanced CD4+ and CD8+ T-cell response was notable, as was the polyfunctionality of the responding cells. Finally, the protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated. These results suggest that YF17D warrants serious consideration as a live-attenuated vector for HIV-1 vaccine development.

Original languageEnglish
Pages (from-to)5676-5685
Number of pages10
JournalVaccine
Volume28
Issue number35
DOIs
Publication statusPublished - Aug 2010
Externally publishedYes

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
AIDS Vaccines
vaccine development
Human immunodeficiency virus 1
HIV-1
vaccines
T-Lymphocytes
T-lymphocytes
Vaccines
Polyproteins
Vaccinia
Cellular Immunity
HIV Infections
Interleukin-2
Vaccinium
mice
interleukin-2
cell-mediated immunity
Antigens

Keywords

  • 17D
  • HIV-1
  • P24
  • Vaccine
  • Yellow fever virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Franco, D., Li, W., Qing, F., Stoyanov, C. T., Moran, T., Rice, C. M., & Ho, D. D. (2010). Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine, 28(35), 5676-5685. https://doi.org/10.1016/j.vaccine.2010.06.052

Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. / Franco, David; Li, Wenjing; Qing, Fang; Stoyanov, Cristina T.; Moran, Thomas; Rice, Charles M.; Ho, David D.

In: Vaccine, Vol. 28, No. 35, 08.2010, p. 5676-5685.

Research output: Contribution to journalArticle

Franco, D, Li, W, Qing, F, Stoyanov, CT, Moran, T, Rice, CM & Ho, DD 2010, 'Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development', Vaccine, vol. 28, no. 35, pp. 5676-5685. https://doi.org/10.1016/j.vaccine.2010.06.052
Franco, David ; Li, Wenjing ; Qing, Fang ; Stoyanov, Cristina T. ; Moran, Thomas ; Rice, Charles M. ; Ho, David D. / Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. In: Vaccine. 2010 ; Vol. 28, No. 35. pp. 5676-5685.
@article{d53b1cdac4da4c2886a3c72e720b3e6a,
title = "Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development",
abstract = "The failure to develop an effective vaccine against HIV-1 infection has led the research community to seek new ways of raising qualitatively different antibody and cellular immune responses. Towards this goal, we investigated the yellow fever 17D vaccine strain (YF17D), one of the most effective vaccines ever made, as a platform for HIV-1 vaccine development. A test antigen, HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24), or between the envelope and the first non-structural protein (YF-E/p24/NS1). In vitro characterization of these recombinants indicated that the gene insert was more stable in the context of YF-E/p24/NS1. This was confirmed in immunogenicity studies in mice. CD8+ IFN-γ T-cell responses against p24 were elicited by the YF17D recombinants, as were specific CD4+ T cells expressing IFN-γ and IL-2. A balanced CD4+ and CD8+ T-cell response was notable, as was the polyfunctionality of the responding cells. Finally, the protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated. These results suggest that YF17D warrants serious consideration as a live-attenuated vector for HIV-1 vaccine development.",
keywords = "17D, HIV-1, P24, Vaccine, Yellow fever virus",
author = "David Franco and Wenjing Li and Fang Qing and Stoyanov, {Cristina T.} and Thomas Moran and Rice, {Charles M.} and Ho, {David D.}",
year = "2010",
month = "8",
doi = "10.1016/j.vaccine.2010.06.052",
language = "English",
volume = "28",
pages = "5676--5685",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "35",

}

TY - JOUR

T1 - Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development

AU - Franco, David

AU - Li, Wenjing

AU - Qing, Fang

AU - Stoyanov, Cristina T.

AU - Moran, Thomas

AU - Rice, Charles M.

AU - Ho, David D.

PY - 2010/8

Y1 - 2010/8

N2 - The failure to develop an effective vaccine against HIV-1 infection has led the research community to seek new ways of raising qualitatively different antibody and cellular immune responses. Towards this goal, we investigated the yellow fever 17D vaccine strain (YF17D), one of the most effective vaccines ever made, as a platform for HIV-1 vaccine development. A test antigen, HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24), or between the envelope and the first non-structural protein (YF-E/p24/NS1). In vitro characterization of these recombinants indicated that the gene insert was more stable in the context of YF-E/p24/NS1. This was confirmed in immunogenicity studies in mice. CD8+ IFN-γ T-cell responses against p24 were elicited by the YF17D recombinants, as were specific CD4+ T cells expressing IFN-γ and IL-2. A balanced CD4+ and CD8+ T-cell response was notable, as was the polyfunctionality of the responding cells. Finally, the protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated. These results suggest that YF17D warrants serious consideration as a live-attenuated vector for HIV-1 vaccine development.

AB - The failure to develop an effective vaccine against HIV-1 infection has led the research community to seek new ways of raising qualitatively different antibody and cellular immune responses. Towards this goal, we investigated the yellow fever 17D vaccine strain (YF17D), one of the most effective vaccines ever made, as a platform for HIV-1 vaccine development. A test antigen, HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24), or between the envelope and the first non-structural protein (YF-E/p24/NS1). In vitro characterization of these recombinants indicated that the gene insert was more stable in the context of YF-E/p24/NS1. This was confirmed in immunogenicity studies in mice. CD8+ IFN-γ T-cell responses against p24 were elicited by the YF17D recombinants, as were specific CD4+ T cells expressing IFN-γ and IL-2. A balanced CD4+ and CD8+ T-cell response was notable, as was the polyfunctionality of the responding cells. Finally, the protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated. These results suggest that YF17D warrants serious consideration as a live-attenuated vector for HIV-1 vaccine development.

KW - 17D

KW - HIV-1

KW - P24

KW - Vaccine

KW - Yellow fever virus

UR - http://www.scopus.com/inward/record.url?scp=77955090269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955090269&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.06.052

DO - 10.1016/j.vaccine.2010.06.052

M3 - Article

C2 - 20600494

AN - SCOPUS:77955090269

VL - 28

SP - 5676

EP - 5685

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 35

ER -